| Home | E-Submission | Sitemap | Editorial Office
Instructions for Authors > For Authors and Reviewers > Instructions for Authors

I. General Information

Journal of the Korean Society of Emergency Medicine (JKSEM) is the official peer-reviewed, open-access, bimonthly journal of the Korean Society of Emergency Medicine. Journal of the Korean Society of Emergency Medicine (JKSEM) focuses on both basic and clinical research of emergency medicine including pathophysiology, epidemiology, diagnosis, prognosis, treatment, and simulation. JKSEM accepts editorials, original articles (brief reports), reviews, letters to the editor, and case reports. JKSEM will be of interest to healthcare professionals in acute care and emergency medicine, pediatric emergency medicine, emergency medical services, emergency procedures, cardiology, neurology, resuscitation, trauma, education, emergency nurses, and so on.
Manuscripts for submission to The Journal of the Korean Society of Emergency Medicine should be prepared according to the following instructions. For issues not addressed in these instructions, the author is referred to the Recommendations of International Committee of Medical Journal Editors (ICMJE; http://www.icmje.org/recommendations/).

II. Research and Publication Ethics

Regarding policies on research and publication ethics not addressed in these instructions, Committee on Publication Ethics (COPE) Guidelines on Good Publication (httP://publicationethics.org/) or Good Publication Practice Guidelines for Medical Journals (http://kamje.or.kr/publishing_ethics.html) should be applied.

1. Statement of Human and Animal Rights and Informed Consent

Any investigations involving humans and animals should be approved by the Institutional Review Board and Animal Care Committee, respectively, of the institution where the study took place. JKSEM will not consider any studies involving humans or animals without the appropriate approval. Informed consent should be obtained, unless waived by the Institutional Review Board, from patients who participated in clinical investigations. Human subjects should not be identifiable, such that patients’names, initials, hospital numbers, dates of birth, or other protected healthcare information should not be disclosed. If experiments involve animals, the research should be based on national or institutional guidelines for animal care and use. Original articles submitted to JKSEM that address any investigation involving humans and animals should include a description about whether the study was conducted under an approval by the Institutional Review Board (with or without patient informed consent) and animal care committee, respectively, of the institution where the study was conducted. JKSEM can request an approval by the Institutional Review Board or Animal Care Committee for the other types of articles when necessary.

2. Authorship and Author’s Responsibility

The corresponding author takes primary responsibility for communication with the journal during the manuscript submission, peer review, and publication process, and typically ensures that all the journal’s administrative requirements, such as providing details of authorship, ethics committee approval, clinical trial registration documentation, and gathering conflict of interest forms and statements, are properly completed, although these duties may be delegated to one or more coauthors. The corresponding author should be available throughout the submission and peer review process to respond to editorial queries in a timely manner, and should be available after publication to respond to critiques of the work and cooperate with any requests from the journal for data or additional information or questions about the paper arise after publication.
Authors are responsible for the whole content of each article. Co-authorship should be based on the following 4 criteria: (1) Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; (2) Drafting the work or revising it critically for important intellectual content; (3) Final approval of the version to be published; and (4) Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Any persons who do not meet the above 4 criteria, may be listed as contributors in the Acknowledgments section.
There is no limitation on the number of authors. Only one author should correspond with the editorial office. JKSEM does not allow adding authors or changing the first or the corresponding authors once its decision of ‘Accept as it is’ is made. If any author wishes to be removed from the byline, he or she should submit a letter signed by the author, as well as all other authors, indicating his or her wish to be deleted from the list of authors. Any change in the name order in the byline requires a letter signed by all authors indicting agreement with the same.

3. Originality and Duplicate Publication

Manuscripts under review or published by other journals will not be accepted for publication in JKSEM, and articles published in this journal are not allowed to be reproduced in whole or in part in any type of publication without permission of the Editorial Board. Figures and tables can be used freely if original source is verified according to Creative Commons Non-Commercial License. It is mandatory for all authors to resolve any copyright issues when citing a figure or table from a different journal that is not open access.

4. Secondary Publication

It is possible to republish manuscripts if the manuscripts satisfy the condition of secondary publication of ICMJE as followings: certain types of articles, such as guidelines produced by governmental agencies and professional organizations, may need to reach the widest possible audience. In such instances, editors sometimes deliberately publish material that is also being published in other journals, with the agreement of the authors and the editors of those journals. Secondary publication for various other reasons, in the same or another language, especially in other countries, is justifiable and can be beneficial provided that the following conditions are met. The authors have received approval from the editors of both journals (the editor concerned with secondary publication must have a photocopy, reprint, or manuscript of the primary version). The priority of the primary publication is respected by a publication interval of at least 1 week (unless specifically negotiated otherwise by both editors).
The paper for secondary publication is intended for a different group of readers; an abbreviated version could be sufficient. The secondary version faithfully reflects the data and interpretations of the primary version. The footnote on the title page of the secondary version informs readers, peers, and documenting agencies that the paper has been published in whole or in part and states the primary reference. A suitable footnote might read: “This article is based on a study first reported in the [title of journal, with full reference].”

5. Process to Manage Research and Publication Misconduct

When the Journal faces suspected cases of research and publication misconduct such as redundant (duplicate) publication, plagiarism, fraudulent or fabricated data, changes in authorship, undisclosed conflict of interest, ethical problem with a submitted manuscript, a reviewer who has appropriated an author’s idea or data, complaints against editors, and etc., the resolving process will be followed by flowchart provided by the Committee on Publication Ethics (http://publicationethics.org/resources/flowcharts). The discussion and decision on the suspected cases are done by Editorial Board.

6. Editorial Responsibilities

The editorial board will continuously work towards monitoring/safeguarding publication ethics: guidelines for retracting articles; maintenance of the integrity of the academic record; preclusion of business needs from compromising intellectual and ethical standard; publishing corrections, clarifications, retractions and apologies when needed; avoiding plagiarism, and fraudulent data. Editors responsibilities shall include: responsibility and authority to rejecte/accept article; avoid conflict of interest with respect to articles they reject/accept; acceptance of a paper when reasonably certain; promoting publication of correction or retraction when errors are found; preservation of the anonymity of reviewers.

7. Conflict of Interest

A conflict of interest may exist when an author (or the author’s institution or employer) has financial or personal relationships or affiliations that could bias the author’s decisions regarding the manuscript. Authors are expected to provide detailed information about all relevant financial interests and relationships or financial conflicts, particularly those present at the time the research was conducted and through publication, as well as other financial interests (such as patent applications in preparation), that represent potential future financial gain. All disclosures of any potential conflicts of interest, including specific financial interests and relationships and affiliations (other than those affiliations listed in the title page of the manuscript) relevant to the subject of their manuscript will be disclosed by the corresponding author on behalf of each coauthor, if any, as part of the submission process. Likewise, authors without conflicts of interest will be requested to state so as part of the submission process. If authors are uncertain about what constitutes a relevant financial interest or relationship, they should contact the editorial office. Failure to include this information in the manuscript will prohibit commencement of the review process of the manuscript. For all accepted manuscripts, each author’s disclosures of conflicts of interest and relevant financial interests and affiliations and declarations of no such interests will be published. The policy requesting disclosure of conflicts of interest applies for all manuscript submissions. If an author’s disclosure of potential conflicts of interest is determined to be inaccurate or incomplete after publication, a correction will be published to rectify the original published disclosure statement. Authors are also required to report detailed information regarding all financial and material support for the research and work, including but not limited to grant support, funding sources, and provision of equipment and supplies as part of the submission process. For all accepted manuscripts, each author’s source of funding will be published.
The authors should disclose all potential conflicts of interest including any research funding, other financial support, and material support for the work, if any exists, in the unblinded full title page. If there is a disclosure, the editors, reviewers, and reader can interpret the manuscripts with this understanding.

III. Copyrights and Publication Fee

1. Copyrights

The manuscript, when published, will become the property of the journal. Copyrights of all published materials are owned by the Korean Society of Emergency Medicine and must not be published elsewhere without written permission. They also follow the Creative Commons Attribution Non-Commercial License available from: http://creativecommons.org/licenses/by-nc/3.0/.

2. Publication Fee

1) 논문의 투고 시에는 투고비 6만원을 대한응급의학회에 입금시켜야 한다. 단, 서신을 투고할 경우에는 투고비를 입금하지 않아도 된다.

신한은행: 140-011-969325 예금주: 대한응급의학회

2) 논문의 게재가 확정되었을 때는 영문초록 교정과 편집, 출판 등에 필요한 투고비 6만원을 대한응급의학회에 입금시켜야 한다.
논문게재료 입금이 확인된 논문에 대해서만 논문 게재 예정 증명서를 발급한다. 도안료 및 제판비, 그밖의 특수 인쇄에 대한 실비는 책임저자가 부담한다.
논문 별책은 배포하지 않으며, 별책이 필요한 경우 비용은 책임저자가 부담한다.

신한은행: 140-011-969325 예금주: 대한응급의학회

3) 학회지 게재용 논문에 관한 문의 및 보내실 곳
부산 서구 구덕로 179 융합의학연구동 4층 응급의학과 의국
편집이사 염 석 란 E-mail: seokrany@pusan.ac.kr
문의 사항 Tel: +82-51-240-7503, Fax: +82-51-253-6472 E-mail: pnuhem@daum.net

IV. 원고 작성에 대한 세부지침

1. 학회지의 논문 원고는 한글 또는 영문으로 작성하는 것을 원칙으로 하고 온라인으로 접수한다(http://submit.jksem.org).
2. 원고형식은 1) 표지(제목, 저자의 성명과 소속), 2) 영문초록 및 중심단어(key Words), 3) 본문, 4) 참고문헌, 5) 표(Tables), 6) 그림 및 사진(Fig.) 순서로 한다. 감사의 글(acknowledgements)을 삽입할 때는 본문 다음으로 한다.
3. 원고작성

1) MS-Word 2000 이상(DOC or DOCX)을 이용하여 A4용지에 10포인트 활자, 줄 간격 200%(또는 2열 간격: double space)으로 작성한다.
2) 원고는 표지(Full title page), 본문(Main body), 표(Table), 그림(Figure), Supplement file, 저작권 이양 동의서(Copyright transfer agreement)로 준비한다.
3) 표지(Full title page)에는 논문 제목, 저자, 책임저자 정보, Running title이 포함된다. 논문 제목과 모든 저자명은 국문 및 영문으로 기재한다. 소속이 다른 저자들이 포함된 경우에는 주 연구기관을 먼저 기록하고, 그 외의 기관은 해당저자 이름 뒤에 어깨번호를 붙이고 소속기관과 일치시켜 번호순으로 기재한다. 표지의 하단에는 책임저자(corresponding author)의 성명, 소속, 주소 및 연락처(전화, 팩스, E-mail)를 기재하며, 기타 연구비 수혜 및 학술 대회 발표 등도 기재한다.
4) 본문(Main body)은 논문의 제목(국문 및 영문), 영문 초록(Abstract), 중심 단어(Key words), 서론(Introduction), 대상과 방법(Materials and Methods), 고찰(Discussion), 결론(Conclusion), 감사의 글(Acknowledgment), 참고문헌(References), 그림 제목과 설명(Figure legend)으로 구성된다. 본문에는 저자 정보가 포함되어서는 안 된다.
5) 영문 초록은 250단어 이내로 하며, 연구의 목적(Purpose), 방법(Methods), 결과(Results), 결론(Conclusion)으로 구분하여 반드시 줄을 바꾸어 기술한다. 단, 증례와 종설은 이 형식을 취하지 않을 수 있다.
6) 영문초록이 끝나는 하단에 3~5개의 중심단어(key words)를 영어로 기재하며, MeSH (Medical Subject Headings)에 공인된 용어를 사용한다.
(MeSH검색 웹 주소: http://www.nlm.nih.gov/mesh/MBrowser.html)
7) 논문의 본문 형식은 다음의 순서로 작성한다. 원저는 서론, 대상과 방법, 결과, 고찰, 결론의 순서로 하고, 증례 는 서론, 증례, 고찰 순서로 하며, 종설은 서론, 본론, 결론 순서로 한다.
8) 참고문헌(References)
모든 참고문헌은 영문 표기를 원칙으로 한다. 한글 논문인 경우에도 영문으로 표기한다. 2) 본문에서 인용되는 순서대로 참고문헌 란에 기재하고 본문에는 어깨번호를 붙여야 한다. 3) 공저일 경우 6인 이하면 전원을 기록하고, 7인 이상일 경우에는 6인 이후에 et al.로 끝맺는다. 학술지명의 표기는 Index Medicus 또는 KoreaMed의 공인된 약자를 사용한다.
참고문헌의 표기양식은 다음과 같다.

(1) 학술지: 저자명. 제목. 잡지명. 발행연도;권(vol):첫쪽-끝쪽(p).
(예) Larsen MP, Eisenberg MS, Cummins RO, Hallstrom AP. Predicting survival from out-of-hospital cardiac arrest: a graphic model. Ann Emerg Med. 1993;22:1652-8.
(2) 단행본: 저자명. 제목. 판(ed). 발행지: 발행사; 년도. 쪽.
(예) Tintinlli JE, Kelen GD, Stapczynski JS. Emergency Medicine. A comprehensive study guide. 4th ed. New York: McGraw-Hill; 1996. p.39-50.
(3) 인터넷 자료의 표기: Available at: http://www.nso.go.kr/. Accessed November 18, 2004.

참고문헌의 수는 원저는 30개 이내, 증례는 20개 이내를 원칙으로 한다. 단 종설인 경우는 예외로 한다.
본문에서 참고문헌은 순서대로 어깨번호를 붙이며, 어깨번호는 저자의 성 뒤에 기재하여야 하고 저자의 성이 없 는 경우는 문장의 끝, 마침표 이전에 한쪽 괄호로 위첨자로 표기한다.
(예) Kim1)은 --, --이다2-5).
참고문헌의 번호가 연속적인 경우, 2개 이하이면 모두 순서대로 표기하여야 하며, 3개 이상인 경우는 “-”을 사용하여 표기한다.
(예) ... 한다2,3).(연속된 2개 이하의 참고문헌의 표기)
... 한다2-6).(연속된 3개 이상의 참고문헌의 표기)
저자가 2명 이하일 때는 저자의 성을 다 쓰며, 3명 이상일 때에는 첫 저자의 성에 “등”을 붙인다.
(예) Nogueras와 Williams3))는--, Goldberg 등4)은--
참고문헌의 작성 시에 한글의 미주 기능의 사용은 불허한다.
인터넷 자료의 인용은 정부(government)의 공식 website (예, ~.go.kr 또는 ~.gov)에 게시된 자료에만 국한한다.

9) 그림 제목 및 설명
본문의 마지막에 그림의 제목과 설명을 기재한다. 그림의 제목은 절로 설명은 완전한 문장의 형태로 영문을 사용하여 기술한다.

10) 표(Table)와 그림 및 사진(Figure)
Table과 figure는 각각 본문에서 인용된 순서대로 번호를 달고, 영문과 아라비아 숫자로 선명하게 Table은 각각 별지에 하나씩 작성한다.
Table 제목은 상단에 절과 구의 형태로 기술한다. Table에서 약자를 사용할 때는 하단에 풀어서 설명한다.

(예) Rad: radiation, Chemo: chemotherapy, NS: not significant. * p<001.
기호는 *,†,‡,§,‖,¶,** 순서로 사용한다.
Figure는 그림 파일(JPG, JPEG, TIFF)로 저장, 첨부하여야 하고 논문의 Figure 번호 및 순서, 설명이 일치하여야 한다. 그림은 원본이어야 하며 타 논문의 그림을 인용할 때는 원칙적으로 원저자의 동의를 얻도록 한다. 동일 번호에서 여러 장의 사진 또는 그림이 있는 경우, 아라비아 숫자 이후에 A, B, C 글자를 기입하여 표시한다.
(예) Fig. 1A --, Fig. 1B --
현미경 사진인 경우 염색방법 및 배율을 기록한다.
(예) H&E stain, ×400

4. 기타
1) 학술용어는 최신판 대한의사협회 발행 의학용어집에 수록된 것을 준용하며, 적절한 번역어가 없는 의학용어나, 고유명사, 지명, 인명, 약품명, 단위 등은 영자로 직접 표기할 수 있다.
2) 번역어가 있으나, 의미전달이 어려운 경우에는 그 용어를 처음 번역할 때 번역어 다음에 괄호 안에 원어로 표기하고 그 후로는 번역어만 사용한다.
3) 영문약자를 사용해야 할 경우에는 처음 사용할 때 풀어쓴 후 괄호 안에 기입한다.
4) 숫자는 아라비아숫자, 도량형은 미터법을 사용하고 모든 단위는 국제표준(SI)단위를 사용하는 것을 원칙으로 한다(예: m, kg, ml, mmHg, sec. 등).
5) 장비, 시약 및 약품은 괄호 안에 제조회사, 도시 및 국적을 명기한다.
6) 한글로 작성된 단어와 인접한 괄호 사이는 띠워 쓰기를 하지 않는다. 단, 영문으로 문장이 구성되어 있을 때에는 영어단어와 접해 있는 괄호는 띠워 쓰기를 한다.
(예) 병원이외의 장소에서 심정지가 발생한 환자(병원 전 심정지환자), advanced cardiovascular life support(ACLS)

5. 서신(correspondence) 투고 요령
1) 대한응급의학회지에 게재된 논문에 대한 독자의 의견과 저자의 견해를 서술한 원고로서, 논문이 발표된 후 4개월 이내에 투고되어야 한다.
2) 진취적인 비평, 의견 또는 특정 주제에 관한 개인적인 의견을 서신 형태로 제출한다.
3) 전체 분량은 2000자 이내로 하고 필요에 따라 각각 1개 이내의 표, 사진을 포함할 수 있다. 참고문헌은 5개 이내로 한다.
4) 서신의 시작 부분은‘편집자에게’로 시작하여야 한다.
5) 편집자는 원저자의 답변을 함께 게재할 수 있다.
6. 본 투고규정에 언급되지 않은 사항은 International Committee on Medical Journal Editors의 Uniform Requirements of Manuscripts Submitted to Biomedical Journals (Vancouver style, 2006년 개정판)의 규정에 준한다.

V. Submitting Manuscripts to JKSEM

1. First Submission

Log in is required for the first time user. If you do not have an account, click “Register” button and make your account. ID should be your email address being actively used now. If you have an account but forgot your password, click the “Forgot Your Password?” button. Your password will be given to your email address on your request. To begin, enter your User ID and password into the boxes provided, and click. At the welcome screen, click “Submit a Manuscript” button. After that, click “New Submissions” button to submit your new manuscript and follow steps 1-7.

Step 1. Title, abstract, and corresponding author: Choose manuscript type, and enter your title and abstract into the appropriate boxes. If you need to insert a special character, click the “Special Characters” button. If you are submitting a manuscript that does not require an Abstract, please type N/A in the Abstract box. Please click the check box, if the corresponding author is the first author. You have to describe the “Article Summary” in all types of manuscript.
Step 2. Authors: Enter the personal information for the first author in the boxes under “Add the First Author.”
Step 3. File upload: The manuscript file (main body) should not include author’s name or name of affiliation. Upload and select the correct file designation for each.
Step 4. PDF conversion: Merger file will be created as pdf format.
Step 5. Additional Info .
Step 6. Preview: Review the information in the Preview chart for correctness; make changes if needed. If you have not completed a required step, you will not be able to submit your manuscript.
Step 7. Submit: Once it is submitted, you will be able to monitor the progress of your manuscript through the peer review process.

2. Following Submission

A Major Revision and a Minor Revision should be submitted within 180 days and 60 days, respectively, of the decisions. Otherwise, the manuscript will be treated as a new submission.
Please carefully read and follow the instructions written here and those included in the manuscript decision e-mail. To start the submission of a revised manuscript, log in at http://submit.jksem.org/. Click the “Manuscripts in Revision” queue in the “My Manuscripts” area. Then, find the submission you wish to start the revision process for and click on the “Create Revision” link for that manuscript.
To continue with a revised manuscript that has yet to be submitted, click on the “Revised Manuscripts in Draft” queue in the “My Manuscripts” area. Find the submission you wish to continue with and then click on the “Continue Submission” button.
Please submit a point-by-point response to the editor/reviewer comments by directly pasting it in the box provided in “View and Response to Decision Letter” page as well as by uploading the same as a Microsoft Word document file (DOC/DOCX) on the “File Upload” page.
Any changes in the authorship should be reported to the editor in the cover letter.
For file uploading, if you have updated a file, please delete the original version and upload the revised file. To designate the order in which your files appear, use the dropdowns in the “order” column on the “File Upload” page.
For a revision, we require two copies of the Main Document. Each should be a Microsoft Word document. The FIRST COPY should represent the final “clean” copy of the manuscript. The SECOND “annotated” COPY should have changes tracked using the track changes function in Microsoft Word with marginal memos indicating changes (e.g., E-1 indicates a response to comment #1 of the Editor; R2-3 indicates a response to comment #3 of Reviewer #2).

VI. Review Process of JKSEM

1. The submitted manuscript will first be evaluated at the editorial office regarding the completeness of the submitted materials and their suitability to JKSEM. Modifications/corrections may be requested from the authors at this stage before starting the peer review.
2. Submitted manuscripts will generally be reviewed by the editors, as well as two to three peer reviewers who are experts in the submitted subject matter and the peer reviewers will make suggestions to the editor (s).
3. JKSEM performs double-blinded peer review of the submitted manuscripts. Neither the peer reviewers nor the authors are revealed to each other.
4. The authors can monitor the progress of the manuscript throughout the review process at the submission site (http://submit.jksem.org/)
5. Submitted manuscripts will be rendered one of the following decisions: Accept: The manuscript is accepted for publication. Minor Revisions: A revision needs to be submitted within 60 days of the decision. Otherwise, the manuscript will be treated as a new submission. Major Revisions: A revision needs to be submitted within 180 days of the decision. Otherwise, the manuscript will be treated as a new submission. Reject, Resubmission allowed: The authors are allowed to resubmit their work. However, it is effective only when they are able to respond to the various reviewer comments and make substantial changes to the study. The resubmitted manuscript will be treated as a new submission. Reject, No further consideration: The paper will no longer be considered for publication.
6. The decision to accept a manuscript is not based solely on the scientific validity and originality of the study content; other factors are considered, including the extent and importance of new information in the paper as compared with that in other papers being considered, the Journal’s need to represent a wide range of topics, and the overall suitability for JKSEM.
7. Decision letters usually, but not always, convey all factors considered for a particular decision. Occasionally, the comments to the authors may appear to be inconsistent with the editorial decision, which takes into consideration reviewers’ comments to the editor, as well as the additional factors listed above.
8. If the author (s) believe that the journal has rejected their article in error, perhaps because the reviewers have misunderstood its scientific content, an appeal may be submitted by e-mail to the editorial office (dremkks@snubh.org). However, appeals are ineffective in most cases and are discouraged.

Editorial Office
The Korean Society of Emergency Medicine
101-3104, Brownstone Seoul, 464 Cheongpa-ro, Jung-gu, Seoul 06351, Korea
TEL: +82-51-240-7503   FAX: +82-51-253-6472   E-mail: pnuhem@daum.net
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © The Korean Society of Emergency Medicine. All rights reserved.